Development: VGV-L: Lyme Disease

Using the TPT technology, an injection called VGV-L has been developed to treat Lyme disease, an illness that saw a 100% increase in CDC-confirmed cases from 1991 to 2006. Animal studies have been completed with positive results. We are now in the process of introducing our research to the FDA.

This research was supported by grants from two not-for-profit organizations that saw the promise in our approach helping enable us to reach this phase of development. The proposed therapy, like several others in our R&D pipeline, is based on TPT and uses synthetic peptides to "trick" cells that may be responsible for harmful symptoms, making them vulnerable to the body's natural immune response mechanism.